Skip to main content

Table 2 Summary the DVH analysis for the reference and the RapidPlan plans for the entire cohort of validation patients from the 3 clinics

From: A broad scope knowledge based model for optimization of VMAT in esophageal cancer: validation and assessment of plan quality among different treatment centers

  Objective Reference RapidPlan p
PTV
 Mean [%] 100 % 100.0 ± 0.0 100.0 ± 0.0 -
 D1% [%] <107 % 104.2 ± 3.2 103.8 ± 3.1 -
 V95% [%] >95 % 97.3 ± 2.9 98.0 ± 1.2 -
 St. Dev. [%] <5 % 2.1 ± 0.1 2.0 ± 0.1 -
Left lung
 Mean [Gy] <15Gy 8.9 ± 4.2 9.1 ± 4.8 -
 V20Gy [%] <20% 12.4 ± 10.2 12.6 ± 11.0 -
Right lung
 Mean [Gy] <15Gy 9.2 ± 4.8 9.1 ± 5.2 -
 V20Gy [%] <20 % 12.1 ± 11.3 12.2 ± 11.7 -
Heart
 Mean [Gy] <25Gy 11.9 ± 9.9 10.7 ± 8.3 0.03
 V30Gy [%] <30 % 10.3 ± 16.1 7.0 ± 8.9 0.07
Spine
 D1cm3 [Gy] <45Gy 26.2 ± 11.5 23.6 ± 9.7 0.001
Liver
 Mean <15Gy 8.5 ± 5.9 8.6 ± 6.4 -
Spleen
 Mean [Gy] <20Gy 14.3 ± 7.6 12.3 ± 6.3 0.004
 D1% [Gy] <40Gy 32.6 ± 10.6 30.6 ± 11.0 -
Left kidney
 V15Gy [%] <35 % 16.4 ± 16.9 12.7 ± 18.7 0.03
Right kidney
 V15Gy [%] <35 % 4.7 ± 7.3 3.4 ± 5.0 -
Stomach
 D1% [Gy] <50Gy 43.3 ± 8.8 42.5 ± 9.9 0.07
Small bowel
 Mean [Gy] <10Gy 6.6 ± 3.1 6.3 ± 3.0 0.03
 D1% [Gy] <45Gy 25.6 ± 9.2 24.6 ± 8.6 -